Subject(s)
Blood Coagulation Disorders , COVID-19 , Blood Coagulation Disorders/therapy , Consensus , Hemostasis , Humans , SARS-CoV-2ABSTRACT
La infección por el coronavirus SARS-CoV-2, causante de la enfermedad denominada COVID-19, provoca alteraciones fundamentalmente en el sistema respiratorio. En los pacientes graves, con frecuencia la enfermedad evoluciona a un síndrome de distrés respiratorio agudo que puede predisponer a los pacientes a un estado de hipercoagulabilidad, con trombosis tanto a nivel venoso como arterial. Esta predisposición presenta una fisiopatología multifactorial, relacionada tanto con la hipoxia como con el grave proceso inflamatorio ligado a esta patología, además de los factores trombóticos adicionales presentes en muchos de los pacientes.Ante la necesidad de optimizar el manejo de la hipercoagulabilidad, los grupos de trabajo de las sociedades científicas de Anestesiología-Reanimación y Terapéutica del Dolor (SEDAR) y de Medicina Intensiva, Crítica y de Unidades Coronarias (SEMICYUC) han desarrollado un consenso para establecer unas pautas de actuación frente a las alteraciones de la hemostasia observadas en los pacientes graves COVID-19. Estas recomendaciones incluyen la profilaxis de la enfermedad tromboembólica venosa en pacientes graves y en el periparto, el manejo de los pacientes en tratamiento crónico con fármacos antiagregantes o anticoagulantes, de las complicaciones hemorrágicas en la evolución de la enfermedad y de la interpretación de las alteraciones generales de la hemostasia
The infection by the coronavirus SARS-CoV-2, which causes the disease called COVID-19, mainly causes alterations in the respiratory system. In severely ill patients, the disease often evolves into an acute respiratory distress syndrome that can predispose patients to a state of hypercoagulability, with thrombosis at both venous and arterial levels. This predisposition presents a multifactorial physiopathology, related to hypoxia as well as to the severe inflammatory process linked to this pathology, including the additional thrombotic factors present in many of the patients. In view of the need to optimise the management of hypercoagulability, the working groups of the Scientific Societies of Anaesthesiology-Resuscitation and Pain Therapy (SEDAR) and of Intensive, Critical Care Medicine and Coronary Units (SEMICYUC) have developed a consensus to establish guidelines for actions to be taken against alterations in haemostasis observed in severely ill patients with COVID-19. These recommendations include prophylaxis of venous thromboembolic disease in these patients, and in the peripartum, management of patients on long-term antiplatelet or anticoagulant treatment, bleeding complications in the course of the disease, and the interpretation of general alterations in haemostasis
Subject(s)
Humans , Coronavirus Infections/therapy , Severe Acute Respiratory Syndrome/therapy , Hemostatic Disorders/therapy , Severe acute respiratory syndrome-related coronavirus/pathogenicity , Anticoagulants/administration & dosage , Fibrinolytic Agents/administration & dosage , Platelet Aggregation Inhibitors/administration & dosage , Coronavirus Infections/physiopathology , Thrombophilia/therapy , Catastrophic Illness/therapy , Pandemics , Heparin, Low-Molecular-Weight/administration & dosage , Pregnancy Complications, Infectious/therapyABSTRACT
The infection by the coronavirus SARS-CoV-2, which causes the disease called COVID-19, mainly causes alterations in the respiratory system. In severely ill patients, the disease often evolves into an acute respiratory distress syndrome that can predispose patients to a state of hypercoagulability, with thrombosis at both venous and arterial levels. This predisposition presents a multifactorial physiopathology, related to hypoxia as well as to the severe inflammatory process linked to this pathology, including the additional thrombotic factors present in many of the patients. In view of the need to optimise the management of hypercoagulability, the working groups of the Scientific Societies of Anaesthesiology-Resuscitation and Pain Therapy (SEDAR) and of Intensive, Critical Care Medicine and Coronary Units (SEMICYUC) have developed a consensus to establish guidelines for actions to be taken against alterations in haemostasis observed in severely ill patients with COVID-19. These recommendations include prophylaxis of venous thromboembolic disease in these patients, and in the peripartum, management of patients on long-term antiplatelet or anticoagulant treatment, bleeding complications in the course of the disease, and the interpretation of general alterations in haemostasis.
Subject(s)
Anticoagulants/therapeutic use , Betacoronavirus , Blood Coagulation Disorders/prevention & control , Coronavirus Infections/complications , Platelet Aggregation Inhibitors/therapeutic use , Pneumonia, Viral/complications , Anticoagulants/administration & dosage , Blood Coagulation Disorders/etiology , COVID-19 , Coronavirus Infections/blood , Coronavirus Infections/epidemiology , Female , Hemorrhage/therapy , Humans , Pandemics , Platelet Aggregation Inhibitors/administration & dosage , Pneumonia, Viral/blood , Pneumonia, Viral/epidemiology , Pregnancy , Pregnancy Complications, Hematologic/blood , Pregnancy Complications, Hematologic/etiology , Pregnancy Complications, Hematologic/prevention & control , Pregnancy Complications, Infectious/blood , Pregnancy Complications, Infectious/etiology , Pregnancy Complications, Infectious/prevention & control , SARS-CoV-2 , Thromboembolism/etiology , Thromboembolism/prevention & control , Thrombosis/etiologyABSTRACT
No disponible
Subject(s)
Humans , Platelet Aggregation Inhibitors/administration & dosage , Blood Loss, Surgical/prevention & control , Perioperative Period , Fluid Therapy/methods , Cyclooxygenase Inhibitors/administration & dosage , Purinergic P2Y Receptor Antagonists/administration & dosage , Phosphodiesterase Inhibitors/administration & dosage , Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors , Hemostasis , Anesthesia, Conduction/methodsABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Neurosurgery/methods , Anticoagulants/therapeutic use , Platelet Aggregation Inhibitors/therapeutic use , Venous Thrombosis/drug therapy , Venous Thrombosis/surgery , Thromboembolism/drug therapy , Thromboembolism/surgery , Venous Thromboembolism/drug therapy , Risk Factors , Neurosurgical Procedures/methods , Surveys and Questionnaires , Societies, Medical/organization & administration , Societies, Medical/trends , Pulmonary Embolism/drug therapyABSTRACT
No disponible